Cost-effectiveness of vaccinating for invasive pneumococcal disease in the elderly in the Lazio region of Italy

Monica Merito, Paolo Giorgi Rossi, Jessica Mantovani, Filippo Curtale, Piero Borgia, Gabriella Guasticchi

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Pneumococcal vaccination among the elderly is currently recommended in several western countries. We estimated the cost-effectiveness of a hypothetical vaccination campaign of 65+ year olds in the Lazio region (Italy). Baseline net costs per event averted and life-year gained, at 2001 prices, were €34,681 (95%CI: €28,699 to €42,929) and €23,361, respectively (95%CI: €16,419 to €38,297). Lower bacteraemic pneumonia incidence and vaccine effectiveness increased the net cost per life-year gained (ICER) to €53,899 and €74,313, respectively; in the best-case scenario the ICER was €4249. The case definition of invasive pneumococcal disease and, consequently, vaccine effectiveness are major uncertainties in countries with low incidence of pneumonia.

Original languageEnglish
Pages (from-to)458-465
Number of pages8
JournalVaccine
Volume25
Issue number3
DOIs
Publication statusPublished - Jan 5 2007

Fingerprint

cost effectiveness
Italy
pneumonia
Cost-Benefit Analysis
Pneumonia
Vaccines
vaccination
vaccines
Costs and Cost Analysis
incidence
Immunization Programs
Incidence
Uncertainty
Vaccination
uncertainty

Keywords

  • Cost-effectiveness analysis
  • Elderly
  • Pneumococcal polysaccharide vaccine

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Cost-effectiveness of vaccinating for invasive pneumococcal disease in the elderly in the Lazio region of Italy. / Merito, Monica; Giorgi Rossi, Paolo; Mantovani, Jessica; Curtale, Filippo; Borgia, Piero; Guasticchi, Gabriella.

In: Vaccine, Vol. 25, No. 3, 05.01.2007, p. 458-465.

Research output: Contribution to journalArticle

Merito, Monica ; Giorgi Rossi, Paolo ; Mantovani, Jessica ; Curtale, Filippo ; Borgia, Piero ; Guasticchi, Gabriella. / Cost-effectiveness of vaccinating for invasive pneumococcal disease in the elderly in the Lazio region of Italy. In: Vaccine. 2007 ; Vol. 25, No. 3. pp. 458-465.
@article{2697664ff8a34b6f829ff241c74155a3,
title = "Cost-effectiveness of vaccinating for invasive pneumococcal disease in the elderly in the Lazio region of Italy",
abstract = "Pneumococcal vaccination among the elderly is currently recommended in several western countries. We estimated the cost-effectiveness of a hypothetical vaccination campaign of 65+ year olds in the Lazio region (Italy). Baseline net costs per event averted and life-year gained, at 2001 prices, were €34,681 (95{\%}CI: €28,699 to €42,929) and €23,361, respectively (95{\%}CI: €16,419 to €38,297). Lower bacteraemic pneumonia incidence and vaccine effectiveness increased the net cost per life-year gained (ICER) to €53,899 and €74,313, respectively; in the best-case scenario the ICER was €4249. The case definition of invasive pneumococcal disease and, consequently, vaccine effectiveness are major uncertainties in countries with low incidence of pneumonia.",
keywords = "Cost-effectiveness analysis, Elderly, Pneumococcal polysaccharide vaccine",
author = "Monica Merito and {Giorgi Rossi}, Paolo and Jessica Mantovani and Filippo Curtale and Piero Borgia and Gabriella Guasticchi",
year = "2007",
month = "1",
day = "5",
doi = "10.1016/j.vaccine.2006.08.005",
language = "English",
volume = "25",
pages = "458--465",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Cost-effectiveness of vaccinating for invasive pneumococcal disease in the elderly in the Lazio region of Italy

AU - Merito, Monica

AU - Giorgi Rossi, Paolo

AU - Mantovani, Jessica

AU - Curtale, Filippo

AU - Borgia, Piero

AU - Guasticchi, Gabriella

PY - 2007/1/5

Y1 - 2007/1/5

N2 - Pneumococcal vaccination among the elderly is currently recommended in several western countries. We estimated the cost-effectiveness of a hypothetical vaccination campaign of 65+ year olds in the Lazio region (Italy). Baseline net costs per event averted and life-year gained, at 2001 prices, were €34,681 (95%CI: €28,699 to €42,929) and €23,361, respectively (95%CI: €16,419 to €38,297). Lower bacteraemic pneumonia incidence and vaccine effectiveness increased the net cost per life-year gained (ICER) to €53,899 and €74,313, respectively; in the best-case scenario the ICER was €4249. The case definition of invasive pneumococcal disease and, consequently, vaccine effectiveness are major uncertainties in countries with low incidence of pneumonia.

AB - Pneumococcal vaccination among the elderly is currently recommended in several western countries. We estimated the cost-effectiveness of a hypothetical vaccination campaign of 65+ year olds in the Lazio region (Italy). Baseline net costs per event averted and life-year gained, at 2001 prices, were €34,681 (95%CI: €28,699 to €42,929) and €23,361, respectively (95%CI: €16,419 to €38,297). Lower bacteraemic pneumonia incidence and vaccine effectiveness increased the net cost per life-year gained (ICER) to €53,899 and €74,313, respectively; in the best-case scenario the ICER was €4249. The case definition of invasive pneumococcal disease and, consequently, vaccine effectiveness are major uncertainties in countries with low incidence of pneumonia.

KW - Cost-effectiveness analysis

KW - Elderly

KW - Pneumococcal polysaccharide vaccine

UR - http://www.scopus.com/inward/record.url?scp=33845304311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845304311&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2006.08.005

DO - 10.1016/j.vaccine.2006.08.005

M3 - Article

C2 - 17049685

AN - SCOPUS:33845304311

VL - 25

SP - 458

EP - 465

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 3

ER -